title: Mast cell proteases as pharmacological targets.
abstract: Mast cells are rich in proteases, which are the major proteins of intracellular granules and are released with histamine and heparin by activated cells. Most of these proteases are active in the granule as well as outside of the mast cell when secreted, and can cleave targets near degranulating mast cells and in adjoining tissue compartments. Some proteases released from mast cells reach the bloodstream and may have far-reaching actions. In terms of relative amounts, the major mast cell proteases include the tryptases, chymases, cathepsin G, carboxypeptidase A3, dipeptidylpeptidase I/cathepsin C, and cathepsins L and S. Some mast cells also produce granzyme B, plasminogen activators, and matrix metalloproteinases. Tryptases and chymases are almost entirely mast cell-specific, whereas other proteases, such as cathepsins G, C, and L are expressed by a variety of inflammatory cells. Carboxypeptidase A3 expression is a property shared by basophils and mast cells. Other proteases, such as mastins, are largely basophil-specific, although human basophils are protease-deficient compared with their murine counterparts. The major classes of mast cell proteases have been targeted for development of therapeutic inhibitors. Also, a human β-tryptase has been proposed as a potential drug itself, to inactivate of snake venins. Diseases linked to mast cell proteases include allergic diseases, such as asthma, eczema, and anaphylaxis, but also include non-allergic diseases such as inflammatory bowel disease, autoimmune arthritis, atherosclerosis, aortic aneurysms, hypertension, myocardial infarction, heart failure, pulmonary hypertension and scarring diseases of lungs and other organs. In some cases, studies performed in mouse models suggest protective or homeostatic roles for specific proteases (or groups of proteases) in infections by bacteria, worms and other parasites, and even in allergic inflammation. At the same time, a clearer picture has emerged of differences in the properties and patterns of expression of proteases expressed in human mast cell subsets, and in humans versus other mammals. These considerations are influencing prioritization of specific protease targets for therapeutic inhibition, as well as options of pre-clinical models, disease indications, and choice of topical versus systemic routes of inhibitor administration.
authors.affiliation: Cardiovascular Research Institute, School of Medicine, University of California at San Francisco, CA, United States; Department of Medicine, School of Medicine, University of California at San Francisco, CA, United States; Veterans Affairs Medical Center, San Francisco, CA, United States. Electronic address: George.Caughey@ucsf.edu.
authors.forename: George H
authors.initials: GH
authors.lastname: Caughey
mesh_terms: D000818:Animals; D006801:Humans; D008407:Mast Cells / Q000187:drug effects / Q000201:enzymology*; D058990:Molecular Targeted Therapy / Q000379:methods*; D010447:Peptide Hydrolases / Q000737:chemistry / Q000378:metabolism*
chemical_list: D010447:Peptide Hydrolases
keywords: Basophil; Carboxypeptidase A3; Cathepsin C; Cathepsin G; Cathepsin L; Chymase; Dipeptidylpeptidase I; Mast cell; Protease; Tryptase